Moderate to Severe Inflammatory Acne Vulgaris- Pipeline Insight, 2024

Moderate to Severe Inflammatory Acne Vulgaris- Pipeline Insight, 2024

DelveInsight’s, “Moderate to Severe Inflammatory Acne Vulgaris- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Moderate to Severe Inflammatory Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Moderate to Severe Inflammatory Acne Vulgaris: Understanding

Moderate to Severe Inflammatory Acne Vulgaris: Overview

Acne vulgaris may be defined as any disorder of the skin whose initial pathology is the microscopic microcomedo. The microcomedo may evolve into visible open comedones (“blackheads”) or closed comedones (“whiteheads”). Subsequently, inflammatory papules, pustules, and nodules may develop. Nodulocystic acne consists of pustular lesions larger than 0.5 cm. The presence of excoriations, post inflammatory hyperpigmentation, and scars should be noted. Acne may be triggered or worsened by external factors such as mechanical obstruction (i.e., helmets, shirt collars), occupational exposures, or medications. In 1990, the American Academy of Dermatology developed a classification scheme for primary acne vulgaris.This grading scale delineates three levels of acne: mild, moderate, and severe. Mild acne is characterized by the presence of few to several papules and pustules, but no nodules. Patients with moderate acne have several to many papules and pustules, along with a few to several nodules. With severe acne, patients have numerous or extensive papules and pustules, as well as many nodules. All characteristic lesions of acne vulgaris can occur in skin of colour, but it usually presents with less discernible redness and more post inflammatory hyperpigmentation (pigmented macules) which persists long after the acne lesion has gone. Post-inflammatory hyperpigmentation is often the major reason for seeking medical attention, causing significant psychological effects. Some dermatologists assess the severity of a patient's acne more precisely by using a grading scale. The inflammatory lesions are compared with a set of standard photographs to determine the grade, which may be 1 (very mild) to 12 (exceptionally severe) for example. In clinical trials evaluating acne treatment, the numbers of non-inflamed and inflamed lesions are carefully counted at regular intervals. It is remarkably difficult to count consistently. Treatment for acne depends on the patient's age and sex, the extent and the severity of the acne, how long it has been present, and response to previous treatments.

“Moderate to Severe Inflammatory Acne Vulgaris- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate to Severe Inflammatory Acne Vulgaris pipeline landscape is provided which includes the disease overview and Moderate to Severe Inflammatory Acne Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Moderate to Severe Inflammatory Acne Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Inflammatory Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Moderate to Severe Inflammatory Acne Vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Moderate to Severe Inflammatory Acne Vulgaris.

Moderate to Severe Inflammatory Acne Vulgaris Emerging Drugs Chapters

This segment of the Moderate to Severe Inflammatory Acne Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate to Severe Inflammatory Acne Vulgaris Emerging Drugs

• TVB-2640: Sagimet Biosciences

TVB-2640 is a first-In-Class, Oral Inhibitor of FASN.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Moderate to Severe Acne Vulgaris.

• BOS 356: Boston Pharmaceuticals

BOS 356 (previously known as GSK 3008356), a small molecule selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor, is being developed by Boston. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Moderate to Severe Acne Vulgaris.

Further product details are provided in the report……..

Moderate to Severe Inflammatory Acne Vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Moderate to Severe Inflammatory Acne Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Moderate to Severe Inflammatory Acne Vulgaris

There are approx. 15+ key companies which are developing the therapies for Moderate to Severe Inflammatory Acne Vulgaris. The companies which have their Moderate to Severe Inflammatory Acne Vulgaris drug candidates in the most advanced stage, i.e. phase II include, Sagimet Biosciences.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Moderate to Severe Inflammatory Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate to Severe Inflammatory Acne Vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate to Severe Inflammatory Acne Vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate to Severe Inflammatory Acne Vulgaris drugs.

Moderate to Severe Inflammatory Acne Vulgaris Report Insights

• Moderate to Severe Inflammatory Acne Vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Moderate to Severe Inflammatory Acne Vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate to Severe Inflammatory Acne Vulgaris drugs?
• How many Moderate to Severe Inflammatory Acne Vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate to Severe Inflammatory Acne Vulgaris?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Inflammatory Acne Vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate to Severe Inflammatory Acne Vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sagimet Biosciences
• Boston Pharmaceuticals
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
• Botanix Pharmaceuticals
• Cutia Therapeutics
• Janssen Research & Development, LLC
• Biofrontera Bioscience GmbH
• Braintree Laboratories

Key Products

• TVB-2640
• BOS 356
• BTX 1503
• FMX101
• RA-18C3
• ALA-PDT
• BLI1100